- Home
- MYGN vs SCS Comparison
MYGN vs SCS Comparison
Compare MYGN & SCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- SCS
- Stock Information
- Founded
- MYGN 1991
- SCS 1912
- Country
- MYGN United States
- SCS United States
- Employees
- MYGN N/A
- SCS N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SCS Office Equipment/Supplies/Services
- Sector
- MYGN Health Care
- SCS Consumer Discretionary
- Exchange
- MYGN Nasdaq
- SCS Nasdaq
- Market Cap
- MYGN 1.3B
- SCS 1.2B
- IPO Year
- MYGN 1995
- SCS 1998
- Fundamental
- Price
- MYGN $8.80
- SCS $11.46
- Analyst Decision
- MYGN Hold
- SCS Strong Buy
- Analyst Count
- MYGN 15
- SCS 2
- Target Price
- MYGN $20.43
- SCS $17.00
- AVG Volume (30 Days)
- MYGN 875.3K
- SCS 838.6K
- Earning Date
- MYGN 05-06-2025
- SCS 03-26-2025
- Dividend Yield
- MYGN N/A
- SCS 3.53%
- EPS Growth
- MYGN N/A
- SCS 50.00
- EPS
- MYGN N/A
- SCS 1.02
- Revenue
- MYGN $837,600,000.00
- SCS $3,166,000,000.00
- Revenue This Year
- MYGN $3.03
- SCS $3.00
- Revenue Next Year
- MYGN $8.31
- SCS $3.07
- P/E Ratio
- MYGN N/A
- SCS $11.11
- Revenue Growth
- MYGN 11.21
- SCS 0.20
- 52 Week Low
- MYGN $8.53
- SCS $10.30
- 52 Week High
- MYGN $29.30
- SCS $14.74
- Technical
- Relative Strength Index (RSI)
- MYGN 27.06
- SCS 53.53
- Support Level
- MYGN $8.53
- SCS $10.76
- Resistance Level
- MYGN $10.30
- SCS $11.70
- Average True Range (ATR)
- MYGN 0.44
- SCS 0.34
- MACD
- MYGN -0.01
- SCS 0.08
- Stochastic Oscillator
- MYGN 15.08
- SCS 82.86
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About SCS Steelcase Inc.
Steelcase Inc is a furniture company based in the United States. Its brands such as Steelcase, AMQ, Coalesse, Designtex, and others offer a portfolio of furniture and architectural products and services designed to help customers create workplaces. It markets its products and services to businesses and organizations predominantly through a network of dealers and also sells to consumers in markets around the world through web-based and retail distribution channels. The company's reportable segments include the Americas which generates key revenue, and International.